Skip to Main Content

Paper Details

FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer.
Clin Cancer Res
19
2022
Author NameAffiliation
Lindsey M PhilpotCenter for Drug Evaluation and Research
Julia A BeaverCenter for Drug Evaluation and Research
Julia A BeaverOncology Center of Excellence
  • 1 - 3

Datasets

Release 1.2